Lamisil (Terbinafine)

Terbinafine inhibits the fungal enzyme squalene epoxidase, which is essential for producing ergosterol, a key component of fungal cell membranes. Blocking this step leads to toxic squalene buildup and loss of ergosterol, disrupting the membrane and causing fungal cell death.

The dosage of Lamisil is determined by the prescribing clinician based on the specific infection, patient weight, age, liver function and other clinical factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for terbinafine in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Healthcare providers should evaluate the potential benefits against possible risks before prescribing it to pregnant or nursing individuals.

To request Lamisil, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lamisil belongs to the allylamine class, which differs from azole antifungals that inhibit a later step in ergosterol synthesis. Terbinafine often achieves faster fungal clearance for dermatophyte infections and may be preferred for nail fungus due to its high tissue concentration, while azoles are commonly used for broader fungal spectra.

Lamisil tablets should be stored at room temperature below 25 °C, in the original packaging, protected from moisture and direct sunlight. Keeping the tablets in a dry, cool environment helps maintain their potency throughout the shelf life.

Lamisil is taken orally, usually with a glass of water. The tablet should be swallowed whole and not chewed or crushed, unless the prescriber provides specific instructions for a particular formulation.

Serious risks include liver injury, which may present as elevated liver enzymes or hepatitis, and severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. Patients should report any signs of jaundice, dark urine, rash or fever to their healthcare provider promptly.

Individuals with known hypersensitivity to terbinafine or any component of the tablet should avoid Lamisil. Patients with pre‑existing severe liver disease, or those taking medications that strongly inhibit CYP2D6 without medical supervision, should also be evaluated carefully before use.